Akuchem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 13-12-2024
- Paid Up Capital ₹ 0.50 M
as on 13-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2021
About Akuchem Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Aaliahamad Peerzade, Devdutta Patil, and Kauser Peerzade serve as directors at the Company.
- CIN/LLPIN
U24299PN2020PLC192149
- Company No.
192149
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2020
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Sangli, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Akuchem Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aaliahamad Peerzade  | Managing Director | 19-Jul-2020 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Devdutta Patil | Director | 03-Feb-2022 | Current |
| Kauser Peerzade | Director | 25-Jan-2022 | Current |
Financial Performance of Akuchem Pharmaceuticals.
Enhance accessibility to Akuchem Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Akuchem Pharmaceuticals?
Unlock access to Akuchem Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aklema Pharmaceuticals LimitedActive 2 years 7 monthsAaliahamad Peerzade and Kauser Peerzade are mutual person
- Aasp Business Empire Private LimitedActive 11 months 30 days
Aaliahamad Peerzade and Kauser Peerzade are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Akuchem Pharmaceuticals?
Akuchem Pharmaceuticals has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akuchem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akuchem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
